The forecast for calcium channel blocking medicine sales in Canada indicates a slight decline from 2024 to 2028. The per capita sales are projected to decrease each year, starting at $7.6 in 2024 and gradually tapering to $7.1 by 2028. Compared to 2023, when the sales were slightly higher, this represents a minor but consistent downward trend.

Year-over-year variations reflect a modest decline, with an average annual decrease anticipated based on a 5-year compound annual growth rate (CAGR). This suggests a stable but gradually diminishing demand over the forecast period.

Future trends to watch for:

Potential shifts in market demand driven by emerging generic alternatives.
Healthcare policy changes that may impact drug pricing and accessibility.
Technological advancements in cardiovascular treatment affecting traditional medicine consumption.